Medical Doctor Program year 2019 Source: CMS Open Payments, 2026 publication

Thomas Jamison

Integrative Medicine Southern Pines, NC Medical Doctor

NPI 1962476077 CMS profile 133950

1690 US Highway 1 S, Suite 300, Southern Pines, NC 28387

Open in the dashboard

General payments

$287

19 records reported · program year 2019

Research payments

$0

Paid to them · None reported · program year 2019

Ownership & investment interest

$0

None reported

Through program year 2019, Thomas Jamison of Southern Pines, NC is reported in the CMS Open Payments database as having received $287 across 19 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

By program year

1 row
Year Kind Relative to this record's peak year Amount Records
2019 General $287 19

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Thomas Jamison
  • Integrative Medicine median
  • Middle half of Integrative Medicine
  • National median

In program year 2025, general payments to Thomas Jamison were reported at $0. Among 30 Integrative Medicine profiles paid that year, the median was $106 and the middle half received between $22 and $416.

Show as a table
Year Thomas Jamison Integrative Medicine median Middle half National median
2019 $287 — — $163
2020 $0 — — $114
2021 $0 — — $132
2022 $0 — — $149
2023 $0 — — $160
2024 $0 $214 $33–$477 $164
2025 $0 $106 $22–$416 $169

Breakdown

Who paid General payments · program year 2019
  1. Novo Nordisk Inc $96 6 payments
  2. Merck Sharp & Dohme Corporation $38 3 payments
  3. GlaxoSmithKline, LLC. $25 2 payments
  4. Radius Health, Inc. $20 1 payment
  5. Abbott Laboratories $17 1 payment
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $17 1 payment
  7. Janssen Pharmaceuticals, Inc $17 1 payment
  8. Sanofi-Aventis U.S. LLC $15 1 payment
  9. AstraZeneca Pharmaceuticals LP $14 1 payment
  10. Kowa Pharmaceuticals America, Inc. $13 1 payment
  11. Other $13 1 payment

Every payment, record by record

What the payments were for General payments · program year 2019
  1. Food and Beverage $287 19 payments
Products named General payments · program year 2019
  1. Ozempic $81 5 payments
  2. STEGLATRO $38 3 payments
  3. JANUVIA $38 3 payments
  4. BELSOMRA $26 2 payments
  5. Tymlos $20 1 payment
  6. FreeStyle Libre $17 1 payment
  7. JARDIANCE $17 1 payment
  8. XARELTO $17 1 payment
  9. INVOKANA $17 1 payment
  10. Tresiba $15 1 payment
  11. Other $175 13 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 15 drugs

Part D claims

256

Prescriptions dispensed, refills included

Drug cost

$3,116

Paid at the pharmacy, in all

Branded share of claims

4.3%

Brand-name drugs, not generics

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Nystatin Generic 14 $690
Fluconazole Generic 24 $581
Progesterone Progesterone, Micronized Brand 11 $434
Trazodone Hcl Generic 13 $388
Rosuvastatin Calcium Generic 26 $185
Gabapentin Generic 16 $173
Losartan Potassium Generic 16 $153
Amlodipine Besylate Generic 24 $100
Levothyroxine Sodium Generic 31 $89
Metformin Hcl Generic 14 $87

The 10 drugs with the highest cost, of 15 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero.

Records

19 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Integrative Medicine in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2019

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record